Head to Head Comparison: Sharps Technology (NASDAQ:STSS) & Stryker (NYSE:SYK)

Sharps Technology (NASDAQ:STSS) and Stryker (NYSE:SYK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Insider & Institutional Ownership

17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 8.7% of Sharps Technology shares are held by insiders. Comparatively, 5.5% of Stryker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Sharps Technology and Stryker’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-110.40%	-73.60%
Stryker	16.34%	23.07%	11.04%

Earnings and Valuation

This table compares Sharps Technology and Stryker”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	N/A	N/A	-$9.84 million	($8.08)	-0.25
Stryker	$21.97 billion	6.43	$3.17 billion	$9.33	39.74

Stryker has higher revenue and earnings than Sharps Technology. Sharps Technology is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sharps Technology has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Sharps Technology and Stryker, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	0	0	0	0	0.00
Stryker	0	3	17	0	2.85

Stryker has a consensus price target of $405.80, suggesting a potential upside of 9.44%. Given Stryker’s stronger consensus rating and higher probable upside, analysts clearly believe Stryker is more favorable than Sharps Technology.

Summary

Stryker beats Sharps Technology on 11 of the 13 factors compared between the two stocks.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.